Home » Δημοσιεύσεις


Δημοσιεύσεις του ιατρού Δρ. Σταφυλά σε Διεθνή Περιοδικά

1. Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Sarafidis P, Maniadakis N. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components. Cost Eff Resour Alloc. 2015 Jun 9;13:10
2. Theodorou M, Stafylas P, Kourlaba G, Kaitelidou D, Maniadakis N, Papademetriou V. Physicians’ perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. Int J Hypertens. 2012;2012:503821. doi: 10.1155/2012/503821. Epub 2012 Nov 28.
3. Giamouzis G, Mastrogiannis D, Koutrakis K, Karayannis G, Parisis C, Rountas C, Adreanides E, Dafoulas GE, Stafylas PC, Skoularigis J, Giacomelli S, Olivari Z, Triposkiadis F. Telemonitoring in chronic heart failure: a systematic review. Cardiol Res Pract. 2012;2012:410820. doi: 10.1155/2012/410820. Epub 2012 Jun 7.
4. Johnston A, Asmar R, Dahlof B, Hill K, Jones DA, Jordan J, Livingston M, Macgregor G, Sobanja M, Stafylas P, Rosei EA, Zamorano J. Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. Br.J.Clin.Pharmacol. 2011; 72:727-730
5. Theodorou M, Kaitelidou D, Galanis P, Middleton N, Theodorou P, Stafylas P, Siskou O, Maniadakis N. Quality of life measurement in patients with hypertension in Cyprus. Hellenic.J.Cardiol. 2011; 52:407-415
6. Kanaki AI, Sarafidis PA, Georgianos PI, Stafylas PC, Kanavos K, Tziolas IM, Lasaridis AN. Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study. J.Hum.Hypertens. 2011;
7. Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br.J.Clin.Pharmacol. 2010; 70:320-334
8. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am.J.Kidney Dis. 2010; 55:835-847
9. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int.J.Cardiol. 2009; 131:298-304
10. Vogiatzis I, Dapcevic I, Sachpekidis V, Stafylas P, Sidiropoulos A, Pittas S, Tsangaris V. Successful thrombolysis of right atrial and ventricular thrombi in a patient with massive pulmonary embolism. Hippokratia. 2009; 13:178-180
11. Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc.Health Risk Manag. 2008; 4:23-30
12. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am.J.Hypertens. 2008; 21:922-929
13. Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J.Clin.Hypertens.(Greenwich.) 2007; 9:751-759
14. Stafylas PC, Sarafidis PA, Lasaridis AN. Rosiglitazone and cardiovascular risk: weighing recent evidence. J.Cardiometab.Syndr. 2007; 2:295-296
15. Stafylas PC, Sarafidis PA, Lasaridis AN, Tsakni E, Niakas DA, Dombros NV, Grekas DM, Bakris GL. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. J.Nephrol. 2007; 20:703-715
16. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, Kazakos K, Yovos J, Bakris GL. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley’s indices in patients with hypertension and type II diabetes. J.Hum.Hypertens. 2007; 21:709-716
17. Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, Kazakos KA, Yovos JG, Tourkantonis AA. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005; 54:1236-1242
18. Stafilas PC, Sarafidis PA, Lasaridis AN, Aletras VH, Niakas DA. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. Am.J.Hypertens. 2005; 18:1233-1240